INNOVATION PHARMACEUTICAL - IPIX STOCK NEWS

Innovation Pharmaceuticals (OTCQB: IPIX) announced the publication of research on Brilacidin in Nature Communications, highlighting its potential in treating fungal infections. The study demonstrated that Brilacidin can enhance the effectiveness of existing antifungal treatments, such as caspofungin, against multiple pathogenic fungi. So far, Brilacidin has shown activity against 14 of the 19 priority fungal pathogens identified by the WHO, with ongoing research in collaboration with NIH/NIAID. The company also welcomed Dr. Gustavo H. Goldman as a Scientific Advisor. His expertise in fungal genetics aims to guide the study of Brilacidin's antifungal properties. The research emphasizes the urgent need for new antifungal agents due to growing drug resistance and limited options in current treatments.

Innovation Pharmaceuticals (OTCQB:IPIX) announced plans for new testing of its drug candidate Brilacidin against difficult fungal pathogens. NIH/NIAID-affiliated researchers will conduct in vitro and in vivo studies. Brilacidin has shown inhibition against 13 of 19 priority fungal pathogens identified by WHO. Particularly, it demonstrated strong inhibition in C. neoformans, which causes 220,000 annual cryptococcal meningitis cases. Additionally, Brilacidin showed synergistic effects with other antifungals. Data supporting Brilacidin’s efficacy was accepted for presentations at major fungal genetics conferences in March 2023.

Innovation Pharmaceuticals (OTCQB: IPIX) announced the accelerated progress of the BeaMed StingRay Laser System, a novel device aimed at treating drug-resistant epilepsy and improving surgical outcomes for brain tumors. CEO Leo Ehrlich highlighted the system's unique safety features and its potential to redefine standards of care. The StingRay System is set for FDA clearance, potentially in 2024, aided by a U.S. distribution partnership with ForTec Medical. Additionally, the company secured a patent for Brilacidin treatments for inflammatory bowel diseases and established a collaborative research agreement with the University of São Paulo to explore Brilacidin's antifungal properties.

Innovation Pharmaceuticals (OTC: IPIX) announced a strategic partnership with Shina Systems to enhance the development of the StingRay Laser System, a groundbreaking technology aimed at treating epilepsy and brain tumors. This agreement aims to expedite the regulatory approval and market launch of the system, leveraging Shina's extensive expertise in medical imaging software. The partnership reinforces BeaMed's commitment to innovating minimally invasive surgical solutions. This collaboration may significantly impact the FDA submission timeline and expedite the launch of a transformative medical product, which could enhance shareholder value.

Innovation Pharmaceuticals (OTCQB:IPIX) announced a significant update on its antifungal candidate, Brilacidin, which is being screened by NIH/NIAID to explore its broad-spectrum antifungal capabilities. Previous studies indicated that Brilacidin enhances existing antifungals and has potent efficacy against C. neoformans. New data shows promise in treating fungal keratitis, affecting up to 1.5 million annually. With ongoing testing planned and emerging threats from fungal infections, Brilacidin's potential could address critical unmet medical needs.

Innovation Pharmaceuticals (IPIX) announces that its strategic partner, BT BeaMedical Technologies, has received FDA clearance for the MANTA surgical laser family. This technology is aimed at enhancing treatment options for epilepsy and various cancers, including brain, prostate, and lung cancers. The MANTA system features five different wavelengths and is set to revolutionize clinical procedures across multiple specialties. BeaMed plans to submit further applications for fiber optics to expand its medical indications, showcasing rapid progress towards commercialization.

Innovation Pharmaceuticals (OTCQB: IPIX) highlights the U.K. NHS's launch of MR-guided laser therapy (MRgLITT) for refractory focal epilepsy as a validation of its investment in BT BeaMedical Technologies. The new procedure offers a minimally invasive treatment alternative, allowing for quicker recovery and targeting of resistant epilepsy cases, expected to commence in early 2023. BeaMed's advanced technology, designed to enhance treatment precision, could significantly expand patient eligibility and improve clinical outcomes for the 70 million individuals affected by epilepsy globally.